The Relationship Between Testosterone-Replacement Therapy and Lower Urinary Tract Symptoms: A Systematic Review (Q35855052)

10 August 2017

title

The Relationship Between Testosterone-Replacement Therapy and Lower Urinary Tract Symptoms: A Systematic Review (English)

1 reference

10 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26616095%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26616095%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26616095%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Craig Niederberger

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26616095%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Allen Seftel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26616095%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Tony Nimeh

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26616095%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Arturo Canto

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26616095%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

language of work or name

English

0 references

publication date

23 November 2015

1 reference

10 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26616095%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26616095%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

page(s)

22-32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26616095%20AND%20SRC:MED&resulttype=core&format=json

Prevalence of symptomatic androgen deficiency in men.

8 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Relationship between lower urinary tract symptoms and serum levels of sex hormones in men with symptomatic benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

An investigation of the relationship between sex-steroid levels and urological symptoms: results from the Boston Area Community Health survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Critical Update of the 2010 Endocrine Society Clinical Practice Guidelines for Male Hypogonadism: A Systematic Analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Rating the quality of evidence and the strength of recommendations using GRADE

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Levels of evidence ratings in the urological literature: an assessment of interobserver agreement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

A safety study of administration of parenteral testosterone undecanoate to elderly men over minimally 24 months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Efficacy and Safety Study of 1.62% Testosterone Gel for the Treatment of Hypogonadal Men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

A Phase IV Prospective Evaluation of the Safety and Efficacy of Extended Release Testosterone Pellets for the Treatment of Male Hypogonadism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Effects of testosterone treatment on bone mineral density in men with testosterone deficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Testosterone replacement therapy by testosterone ointment relieves lower urinary tract symptoms in late onset hypogonadism patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Short-term effects of intramuscular and transdermal testosterone on bone turnover, prostate symptoms, cholesterol, and hematocrit in men over age 70 with low testosterone levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Effects of androgen deficiency and replacement on prostate zonal volumes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Testosterone supplementation does not worsen lower urinary tract symptoms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

The role of estrogens and estrogen receptors in normal prostate growth and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Is testosterone a friend or a foe of the prostate?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Benign prostatic hyperplasia: a new metabolic disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Metabolic syndrome and lower urinary tract symptoms in patients with benign prostatic enlargement: a possible link to storage symptoms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Sex steroid receptors in male human bladder: expression and biological function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Effects of different sex hormones on male rabbit urodynamics: an experimental study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Testosterone changes bladder and kidney structure in juvenile male rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

Estrogen receptor-α is a key mediator and therapeutic target for bladder complications of benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2015.11.006

10.1016/J.UROLOGY.2015.11.006

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26616095%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26616095%20AND%20SRC:MED&resulttype=core&format=json